Kobayashi Takeshi, Namitome Ryo, Hirata Y U, Shiota Masaki, Imada Kenjiro, Kashiwagi Eiji, Takeuchi Ario, Inokuchi Junichi, Tatsugami Katsunori, Eto Masatoshi
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Anticancer Res. 2019 Jun;39(6):3191-3195. doi: 10.21873/anticanres.13457.
BACKGROUND/AIM: To date, several serum prognostic factors have been reported in metastatic prostate cancer. In this study, we examined the prognostic value of these serum markers in Japanese men.
This study included 104 patients with metastatic prostate cancer who were treated with primary androgen-deprivation therapy from 2001 to 2013. Clinicopathological factors including several serum markers were investigated for association with progression-free (PFS) and overall (OS) survival.
During a median follow-up of 48.1 months, median PFS and OS were 24.0 months and 67.4 months, respectively. When adjusted by age, prostate-specific antigen at diagnosis, Gleason score, and clinical stage, serum lactate dehydrogenase value was significantly associated with PFS [hazard ratio (HR)=1.42, 95% confidence interval (CI)=1.15-1.74; p=0.0004] and OS (HR=1.46, 95% CI=1.13-1.82; p=0.0014), in addition to alkaline phosphatase value for OS (HR=1.04; 95% CI=1.00-1.07; p=0.015).
This study demonstrates the prognostic significance of alkaline phosphatase and lactate dehydrogenase values in Japanese men with de novo metastatic hormone-sensitive prostate cancer.
背景/目的：迄今为止，已有多项血清预后因素在转移性前列腺癌中被报道。在本研究中，我们检测了这些血清标志物对日本男性患者的预后价值。
本研究纳入了2001年至2013年期间接受初始雄激素剥夺治疗的104例转移性前列腺癌患者。对包括多种血清标志物在内的临床病理因素进行研究，以探讨其与无进展生存期（PFS）和总生存期（OS）的相关性。
在中位随访48.1个月期间，中位PFS和OS分别为24.0个月和67.4个月。在根据年龄、诊断时的前列腺特异性抗原、Gleason评分和临床分期进行校正后，血清乳酸脱氢酶值与PFS显著相关[风险比（HR）=1.42，95%置信区间（CI）=1.15 - 1.74；p = 0.0004]，与OS也显著相关（HR = 1.46，95% CI = 1.13 - 1.82；p = 0.0014），此外，碱性磷酸酶值与OS相关（HR = 1.04；95% CI = 1.00 - 1.07；p = 0.015）。
本研究证明了碱性磷酸酶和乳酸脱氢酶值对日本初发转移性激素敏感性前列腺癌男性患者的预后意义。
